TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00112112

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
Study: NCT01173536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Oral repeating dose
Study: NCT00112112

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
Study: NCT02948543

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bacillus of Calmette-Guerin (BCG)
Description: A strain of tubercle bacillus which modifies biologic response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus of Calmette-Guerin (BCG)
Description: A strain of tubercle bacillus which modifies biologic response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin (MM)
Description: An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
Study: NCT04606888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation
Description: According to the traditional Chinese medicine 15,three acupuncture points were selected as the target points: bilateral Neiguan ,Yintang and bilateral Zusanli.. A transcutaneous electrical stimulator was used to provide an altered frequency 2/100 Hz,disperse-dense waves,and adjusted intensity which was less than 10mA.
Study: NCT00670540

Intervention type: OTHER
Intervention: procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis
Description: patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
Study: NCT04453787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arch support orthoses with forefoot medial wedge
Description: The degree of forefoot wedge will be 3 degree. If needed, it could be adjusted. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arch support orthoses
Description: The arch support of the orthoses could be adjusted depends on the evaluation of subject. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Flat insole
Description: The flat insole used as a placebo intervention. The shape of this insole is flat, and made by soft EVA. It only provide shock absorbtion without any support. The subjects need to wear the orthoses for at least 30 hour per week during the experiment.
Study: NCT00681811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGT-1111
Description: Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGT-1111
Description: Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
Study: NCT00124605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pamidronate disodium
Description: Given IV
Study: NCT00893945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC/AAT
Description: Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC/AAT-Flu
Description: Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC/KLH
Description: Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
Study: NCT03419624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: daily Insulin injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: daily Insulin injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: daily Insulin injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, if taken before
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin, if taken before
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin, if taken before
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
Study: NCT02767973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wood Smoke Particles (WSP)
Description: After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
Study: NCT01627106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant
Description: Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Administered IV as per product label
Study: NCT00780390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autonomic Function Assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autonomic Function Assessment
Study: NCT00717444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors
Study: NCT02386800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
Study: NCT01135940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-octylcyanoacrylate (Dermabond) closure
Description: Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
Study: NCT04544631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality game as adjunctive pain management tool
Description: A smart phone virtual reality-based pain alleviation tool (VR-PAT).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality game as adjunctive pain management tool
Description: A smart phone virtual reality-based pain alleviation tool (VR-PAT).
Study: NCT00124605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04629521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study: NCT03662373

Intervention type: RADIATION
Intervention: carbon ions radiation therapy
Description: Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
Study: NCT00124605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01698671

Intervention type: DEVICE
Group type: OTHER
Intervention: InterGard Synergy Vascular Graft
Study: NCT01135940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard staple closure
Description: Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
Study: NCT04386122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FABALOFEN 60
Description: Dosage: Single dose of one tablet of test product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of test product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JAPROLOX TABLET
Description: Dosage: Single dose of one tablet of reference product in each period. Administration: 30 minutes before administration, subjects will receive a test meal (high-fat and high-calorie) and finish this meal in 30 minutes or less. Take 1 tablet of reference product with 240 mL of water. Lying position or strenuous activities are not allowed within 2 hours post dose
Study: NCT01050764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regulatory T-cells
Description: To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~* T-reg: 1 x 10e5/kg~* T-con: 3 x10e5/kg~Cohort 2~* T-reg: 3 x 10e5/kg~* T-con: 1 x 10e6/kg~Cohort 3~* T-reg: 1 x 10e6/kg~* T-con: 3 x 10e6/kg~Cohort 4~* T-reg: 3 x 10e6/kg~* T-con: 1 x 10e7/kg
Study: NCT03662373

Intervention type: RADIATION
Intervention: protons radiation therapy
Description: Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
Study: NCT01050764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional T-cells
Description: These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin, rabbit
Description: Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CliniMACS CD34 Reagent System
Description: An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
Study: NCT02416180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SERETIDE MDI
Description: Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo DISKUS Inhaler
Description: Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo MDI
Description: Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
Study: NCT02643927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard 8-weeks MBSR
Description: A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
Study: NCT03314337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic stent: PSOF COOK®
Description: After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
Study: NCT01449929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir 50 mg OAD
Description: 1 x 50 mg tablet OAD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir 800mg OAD
Description: 2 x 400mg tablets OAD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir 100mg OAD
Description: 1 x 100mg tablet OAD
Study: NCT01194505

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic, femoral, obturator nerve blocks
Description: Ultrasound guided blocks with ropivacaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block, posterior lumbar plexus block
Description: Ultrasound and neurostimulator nerve blocks with ropivacaine
Study: NCT04265118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sidewards Tilting Bed
Description: Sidewards tilting of the bed is hypothesized to induce a body position change in sleeping subjects.
Study: NCT04130971

Intervention type: OTHER
Intervention: No intervention, just observation
Description: No intervention, just observation of the differences between groups and within patients.

Intervention type: OTHER
Intervention: No intervention, just observation
Description: No intervention, just observation of the differences between groups and within patients.

Intervention type: OTHER
Intervention: No intervention, just observation
Description: No intervention, just observation of the differences between groups and within patients.

Intervention type: OTHER
Intervention: No intervention, just observation
Description: No intervention, just observation of the differences between groups and within patients.
Study: NCT03434899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise and online support
Description: Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
Study: NCT06614816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oka strain varicella attenuated live vaccine
Description: lyophilized powder, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oka strain varicella attenuated live vaccine
Description: lyophilized powder, subcutaneous injection
Study: NCT04209127

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave treatment via needle antenna
Description: Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)
Description: Embolization via percutaneous catheter
Study: NCT04662710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg Q6W by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered PO QD, 8 mg induction/20 mg consolidation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.
Study: NCT03434899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Person-centered design of health care plan individually adjusted physical exercise.
Study: NCT03445442

Intervention type: PROCEDURE
Intervention: SCP
Description: Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms

Intervention type: PROCEDURE
Intervention: NTR
Description: Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.

Intervention type: PROCEDURE
Intervention: VMR
Description: Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
Study: NCT02643927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-week shortened MBSR
Description: This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
Study: NCT01377441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Saline solution
Description: Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
Study: NCT01145157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signature Knee Guide
Description: Total Knee Arthroplasty performed using Signature Knee Guide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Total Knee Arthroplasty performed using Conventional Instrumentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer Assisted Navigation
Description: Total Knee Arthroplasty performed using Computer Assisted Navigation
Study: NCT03266276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSOPC pathway approach
Description: The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral.
Study: NCT02834962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single bundle ACL reconstruction
Description: anterior cruciate ligament reconstruction using single bundle technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double bundle ACL reconstruction
Description: anterior cruciate ligament reconstruction using double bundle technique